PAR 5.00% 19.0¢ paradigm biopharmaceuticals limited..

Current SP appreciation, page-42

  1. 4,567 Posts.
    lightbulb Created with Sketch. 348
    think it needs a break. phase 3 trial is going to take a long while, and phase 3 probabilities are not high for biotechs in general. theres much higher standard in phase 3. not that this wont be successful, but still a lot of risk from a 1 drug stock.
    Last edited by Nige456: 23/09/19
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.